What was Lycia Therapeutics, Inc.’s price range in the past 12 months?
Lycia Therapeutics, Inc. lowest stock price was $22.19 and its highest was $36.49 in the past 12 months.
What is Lycia Therapeutics, Inc.’s market cap?
Lycia Therapeutics, Inc.’s market cap is $1.52B.
When is Lycia Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Lycia Therapeutics, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Lycia Therapeutics, Inc. pay dividends?
Lycia Therapeutics, Inc. does not currently pay dividends.
What is Lycia Therapeutics, Inc.’s EPS estimate?
Lycia Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lycia Therapeutics, Inc. have?
Lycia Therapeutics, Inc. has 57,680,557 shares outstanding.
Which hedge fund is a major shareholder of Lycia Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LYCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Aetna Wun Trombley
Employees
65
Website
lyciatx.com
Address
400 East Jamie Court, South San Francisco, CA, 94080, US